Evidence map›Paper›PMID 38201860›Full record

ReviewNutrients2023

Are Phe-Free Protein Substitutes Available in Italy for Infants with PKU All the Same?

Elvira Verduci, Martina Tosi, Chiara Montanari, Mirko Gambino, Francesca Eletti, Alessandra Bosetti, Margherita Di Costanzo, Maria Teresa Carbone, Giacomo Biasucci, Laura Fiori and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Elvira VerduciMetabolic Diseases Unit, Department of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan, 20154 Milan, Italy.ORCID 0000-0003-2111-3111
Martina TosiDepartment of Health Sciences, University of Milan, 20146 Milan, Italy.ORCID 0000-0003-4859-5288
Chiara MontanariDepartment of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan, 20154 Milan, Italy.ORCID 0000-0002-4875-6179
Mirko GambinoDepartment of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan, 20154 Milan, Italy.
Francesca ElettiDepartment of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan, 20154 Milan, Italy.
Alessandra BosettiDepartment of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan, 20154 Milan, Italy.
Margherita Di CostanzoU.O.C. Pediatrics and Neonatology, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy.ORCID 0000-0002-8985-770X
Maria Teresa CarboneUOSD Metabolic Diseases, AORN Santobono-Pausilipon, 80122 Naples, Italy.
Giacomo BiasucciU.O.C. Pediatrics and Neonatology, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy.ORCID 0000-0002-7441-9248
Laura FioriDepartment of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan, 20154 Milan, Italy.ORCID 0000-0003-3579-7403
Gianvincenzo ZuccottiDepartment of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan, 20154 Milan, Italy.ORCID 0000-0002-2795-9874
University of Milan · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breastfeeding or standard infant formulas, alongside phenylalanine (Phe)-free protein substitutes, constitute the dietary management for infants with PKU to guarantee protein requirements are met in compliance with metabolic tolerance. This work aims to analyse the nutritional composition of Phe-free infant protein substitutes, in terms of macronutrients, micronutrients and functional components, available for PKU dietary management in Italy. A total of seven infant Phe-free protein substitutes were included in this review, six powder and one liquid. A second analysis was conducted to compare them to the composition of formulas intended for healthy infants, taking into consideration the Commission Delegated Regulation (EU) 2016/127 and Commission Delegated Regulation (EU) 2016/128 for micronutrients. The analysis revealed heterogeneity among protein substitutes suitable for infants with PKU. The energy and protein equivalents (P.Eq.) content are different; all of the substitutes contain docosahexaenoic acid (DHA) and arachidonic acid (ARA), while eicosapentaenoic acid (EPA), fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), human milk oligosaccharides (HMOs) and nucleotides are not present in all the substitutes. More attention should be paid to these infant products to ensure metabolic control of PKU, and also promote proper growth, cognitive neurodevelopment, favourable gut microbiota composition, and immune system health, while reducing the risk for non-communicable diseases (NCDs).

Indexed as

NutrientsPhenylalanineHumansInfantItalyMicronutrientsOligosaccharidesMicronutrientsNutrientsOligosaccharidesPhenylalaninearachidonic acidbioticsdocosahexaenoic acidinfant nutritionnon-communicable diseases preventionPhe-free protein substitutesphenylketonuria

Identifiers

PMID38201860
PMCPMC10780432
OpenAlexW4390058123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.